HJURP PEPTIDES AND VACCINES INCLUDING THE SAME

摘要

Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

主权项

1. An isolated peptide having cytotoxic T lymphocyte (CTL) inducibility, wherein the peptide is selected from the group consisting of:
(a) an isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, 7, 18 and 23; (b) an isolated peptide comprising an amino acid sequence modified by substituting, deleting, inserting, or adding 1, 2, or several amino acid residues to an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4, 7, 18 and 23; (c) an isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 30, 31, 32, 35, 37, and 43; and (d) an isolated peptide comprising an amino acid sequence modified by substituting, deleting, inserting, or adding 1, 2, or several amino acid residues to an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 30, 31, 32, 35, 37, and 43.